In support of the American College of CHEST Physicians (ACCP) 75th Anniversary, CSL Behring will be offering an educational activity at our booth to help increase awareness about alpha-1 antitrypsin deficiency and raise funding for the Alpha-1 Foundation/CHEST Research Award. We will donate up to $5,000 for this annual Award–but we need your help.
Join us at booth #1122 on November 2-4 to participate and help support ACCP's ongoing commitment to clinical chest medicine.
Important Safety Information
Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
As with other Alpha-1 therapies, Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please click here for full prescribing information for Zemaira.
